Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles

DSpace/Manakin Repository

Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles

Citable link to this page

 

 
Title: Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles
Author: Yu, Ting; Zhao, Shengnan; Li, Ziqiang; Wang, Yi; Xu, Bei; Fang, Dailong; Wang, Fazhan; Zhang, Zhi; He, Lili; Song, Xiangrong; Yang, Jian

Note: Order does not necessarily reflect citation order of authors.

Citation: Yu, T., S. Zhao, Z. Li, Y. Wang, B. Xu, D. Fang, F. Wang, et al. 2016. “Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles.” International Journal of Molecular Sciences 17 (12): 1977. doi:10.3390/ijms17121977. http://dx.doi.org/10.3390/ijms17121977.
Full Text & Related Files:
Abstract: Hypertension has become a significant global public health concern and is also one of the most common risk factors of cardiovascular disease. Recent studies have shown the promising result of peptides inhibiting angiotensin converting enzyme (ACE) in lowering the blood pressure in both animal models and humans. However, the oral bioavailability and continuous antihypertensive effectiveness require further optimization. Novel nanoparticle-based drug delivery systems are helpful to overcome these barriers. Therefore, a poly-(lactic-co-glycolic) acid nanoparticle (PLGANPs) oral delivery system, of the antihypertensive small peptides Val-Leu-Pro-Val-Pro (VLPVP, VP5) model, was developed in this study and its antihypertensive effect was investigated in spontaneously hypertensive rats (SHRs) for the first time. The obtained VP5 nanoparticles (VP5-NPs) showed a small particle size of 223.7 ± 2.3 nm and high entrapment efficiency (EE%) of 87.37% ± 0.92%. Transmission electronic microscopy (TEM) analysis showed that the nanoparticles were spherical and homogeneous. The optimal preparation of VP5-NPs exhibited sustained release of VP5 in vitro and a 96 h long-term antihypertensive effect with enhanced efficacy in vivo. This study illustrated that PLGANPs might be an optimal formulation for oral delivery of antihypertensive small peptides and VP5-NPs might be worthy of further development and use as a potential therapeutic strategy for hypertension in the future.
Published Version: doi:10.3390/ijms17121977
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187777/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29738921
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters